Pancreatic Cancer Brief — Daraxonrasib doubles survival in pancreatic cancer trials

Digest Newsletter

1 week ago

Featuring
Mike Zeinfeld Mike Zeinfeld
Pancreatic Cancer Brief — Daraxonrasib doubles survival in pancreatic cancer trials
Digest Newsletter · Jun 13, 2026
Pancreatic Cancer Brief — Daraxonrasib doubles survival in pancreatic cancer trials

Welcome to Matters.com™ beta. A new social platform to share what matters. More information? Click here.

A late-stage clinical result this week changes how some doctors will treat advanced pancreatic cancer, and several industry moves point to faster work on hard-to-drug mutations. Below are the facts, what is already available to patients, and other items that matter if you follow trials, combination approaches, and genetic risk.

Daraxonrasib doubles survival vs. chemo in trials

A clinical trial reported that the KRAS-targeting pill daraxonrasib roughly doubled overall survival compared with standard chemotherapy for patients with advanced pancreatic cancer. The result is prompting oncologists to offer access outside trial settings; physicians can apply for patient access while regulatory review continues. For clinicians and families tracking trial options, the study shifts how we weigh targeted therapy vs. cytotoxic chemo — read the local report and note that the drug is not yet FDA-approved but is being used under expanded access programs.

Pharma buys tech to target KRAS

Johnson & Johnson paid $1 billion for technology aimed at 'undruggable' cancer proteins such as KRAS, a move that could accelerate targeted options for pancreatic cancers driven by these mutations. Details on the acquisition.

Tumor microenvironment atlas

A new single-cell atlas maps cell types and interactions in the pancreatic tumor microenvironment, offering actionable insight for immunotherapy and combination strategies. See the study summary.

Metal-free prodrug halts metastasis

Researchers at Weill Cornell report a metal-free carbon monoxide prodrug that stopped metastatic spread in preclinical pancreatic cancer models, suggesting a novel adjunct that could pair with existing therapies. Preclinical findings.

Why KRAS matters in pancreatic cancer

KRAS mutations are the single most common genetic driver in pancreatic ductal adenocarcinoma, present in about 90% of tumors; they promote cell growth and make the disease resistant to many standard therapies. Targeting KRAS directly has been difficult, so recent drugs that inhibit specific KRAS variants or their pathways represent a major shift in treatment strategy.